HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.

AbstractBACKGROUND:
A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases.
CASE REPORT:
We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.
CONCLUSION:
Further studies are required to elucidate the association between anti-EGFR antibodies and ILD.
AuthorsTakeshi Yamada, Toshikazu Moriwaki, Kenji Matsuda, Yoshiyuki Yamamoto, Akinori Sugaya, Daisuke Akutsu, Tetsuya Murashita, Shinji Endo, Ichinosuke Hyodo
JournalOnkologie (Onkologie) Vol. 36 Issue 4 Pg. 209-12 ( 2013) ISSN: 1423-0240 [Electronic] Switzerland
PMID23548971 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2013 S. Karger AG, Basel.
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Panitumumab
Topics
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Colorectal Neoplasms (drug therapy, secondary)
  • Humans
  • Lung Diseases, Interstitial (chemically induced, diagnosis, prevention & control)
  • Male
  • Middle Aged
  • Panitumumab
  • Treatment Failure
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: